Dialysis industry news

Stories from the dialysis comunity across the globe.

Manitoba to help home dialysis patients pay utility costs - CBC.ca PDF Print

Manitoba's health minister says the province will reimburse home dialysis patients for their extra utility costs.

Sharon Blady says water and electricity bills can add up for patients who are treated at home.

Repayment will be based on utility use during scheduled dialysis and on the type of machine used.

She says home dialysis is still almost nearly 50 per cent less costly than in hospitals.

That's because it reduces the need for hospital space and requires fewer health-care workers.

The reimbursements will be administered by the Manitoba branch of the Kidney Foundation of Canada.

"We hope these new supports will encourage more patients to undergo hemodialysis treatment in the comfort of their own home and enjoy a better quality of life," Blady said in a release Thursday.


Parker Receives Award from American Society of Nephrology - UB School of Medicine and Biomedical Sciences News PDF Print

Parker Receives Award from American Society of Nephrology
UB School of Medicine and Biomedical Sciences News
Mark D. Parker, PhD, received a grant from the American Society of Nephrology Foundation for Kidney Research to help further his research on acidosis. Parker Receives Award from American Society of Nephrology. Published August 20, 2015.


Manitoba government will cover utility bills for home dialysis patients - Winnipeg Free Press PDF Print

Manitoba will become the first province to pay the added water and electricity costs for dialysis patients who are approved for treatment at home.

Health Minister Sharon Blady says the goal for home hemodialysis patients is not only to lessen the stress of treatment, but to reduce the cost of hospital or clinical treatment.

The number of dialysis patients is increasing with more diabetes patients and an aging population. As a result, Manitoba has among the highest incidence of new patients and prevalence (total patients) of dialysis use in Canada. It’s estimated that each year 80 new patients need dialysis, meaning 14 more clinical spots have to open for treatment — a rate that’s taxing the health-care system.

"We’ve got these challenges where we’ve got increasing numbers," Blady said Thursday. ‘Once people get trained for it, and know how to do it at home, they find it really empowering.

"To me it does wonderful things," she added. "We’re able to give a better quality of care at home, which gives a better quality of life, and it saves money that can be reinvested for caring more folks."

The additional hydro and water costs for home treatment range from about $700 to $2,000 a year in Winnipeg, she added.

The reimbursement program will be administered by the Manitoba Branch of the Kidney Foundation of Canada. More details about the provincial reimbursement program will be available for those who are eligible in early October. It will be backdated to last April.

Blady said the operating cost for home dialysis is about 50 per cent less than what it would be in a hospital. Home treatment reduces exposure to hospital bugs and infections.

Mukhtiar Singh said when he began nocturnal home hemodialysis in 2009 — he’s been on dialysis for 20 years—he saw his utility bills jump by $1,800 a year.

Singh, 67, is member of a patient advocacy group that pushed for the reimbursement program. His treatment takes about eight hours five nights a week, with his home water-treatment system being the largest expense.

He said if the province can get 300 people on home hemodialysis, the health-care system could save $40,000 to $50,000 a year per patients.

"We’d be looking at $12 million to $15 million per year saving to Manitoba Health," he said. "It saves money. It takes pressure off the system, and the patient’s quality of life gets better."

Dr. Mauro Verrelli of the St. Boniface General Hospital, medical director for Manitoba Renal Program, said many patients with less complex treatments can be treated at home.

"I think the strength of this program is that people who may have not wanted to do home hemodialysis because they were worried about paying up to $2,000 a year in utility bills now can say they don’t have that problem," Verrelli said.

He said a reasonable target is have 30 per cent of hemodialysis (artificial kidney machine) and peritoneal dialysis (blood is cleaned inside the body, using it as a natural filter, rather than being cleaned outside in a machine) patients treated at home.

He said right now four per cent of hemodialysis patients are treated at home. About 20 per cent of peritoneal dialysis patients are treated at home.

"If we went to 30 per cent over the next few years, that would be great," he said. "Unfortunately, there is a net yearly growth that is taxing the health system, and that everybody is striving to do their due diligence to contain, but diabetes rates are increasing, chronic disease rates are increasing and people are aging. More people need dialysis."

This e-mail address is being protected from spambots. You need JavaScript enabled to view it


Liraglutide Effective for Weight Loss in Type 2 Diabetes - Renal and Urology News PDF Print
August 20, 2015 Liraglutide Effective for Weight Loss in Type 2 Diabetes - Renal and Urology News
More weight loss for 3.0 mg liraglutide versus placebo among overweight/obese with type 2 diabetes.

(HealthDay News) -- For overweight or obese patients with type 2 diabetes, subcutaneous liraglutide (3.0 mg) results in more weight loss than placebo over 56 weeks, according to a study published in the Journal of the American Medical Association.

Melanie J. Davis, M.D., from the University of Leicester in the United Kingdom, and colleagues examined the efficacy and safety of liraglutide versus placebo in overweight or obese adults with type 2 diabetes. A total of 846 adults from 126 sites were randomized to once-daily subcutaneous liraglutide 3.0 mg (423 participants), liraglutide 1.8 mg (211 participants), or placebo (212 participants), all as an adjunct to dietary deficit and increased physical activity.

The researchers found that weight loss was 6.0, 4.7, and 2.0%, respectively, for liraglutide 3.0 mg, liraglutide 1.8 mg, and placebo (P = 0.001 for both). Weight loss of 5% or more occurred in 54.3, 40.4, and 21.4%, respectively, of the liraglutide 3.0 mg, liraglutide 1.8 mg, and placebo groups (P < 0.001 for both); the corresponding values for weight loss of more than 10% were 25.2, 15.9, and 6.7% (P < 0.001 for liraglutide 3.0 mg versus placebo and P = 0.006 for liraglutide 1.8 mg versus placebo).

"Among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resulted in weight loss over 56 weeks," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study. Liraglutide is a Novo Nordisk proprietary compound.


  1. Davies, MJ; Bergenstal, R; Bode, B; et al. JAMA. 2015;314(7):687-699; doi:10.1001/jama.2015.9676.


Research and Markets: End-Stage Kidney Disease - Global API Manufacturers ... - Business Wire (press release) PDF Print

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2s6vjm/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015" report to their offering.

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the End-Stage Kidney Disease.

A key objective of The report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).


  • A snapshot of the global Market therapeutics scenario for End-Stage Kidney Disease.
  • A review of the marketed products under prescription for End-Stage Kidney Disease, regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges.

Key Topics Covered:

  • Marketed Drugs
  • Marketed Details of Drugs by Application Type
  • Marketed Details of Drugs (NDA) by Marketing Status
  • Marketed Details of Drugs by Patent Expiration Timeline
  • Active Pharmaceutical Ingredient (API) Manufacturers Assessment
  • API Manufacturers by United States Drug Master File (US DMF) Status
  • API Manufacturers by US DMF Status
  • API Manufacturers in Europe by Country
  • API Manufacturers in India by State
  • API Manufacturers in China by Province
  • Marketed Details of Approved Drugs by Geography
  • Active Pharmaceutical Ingredient Manufacturers Assessment for Phase III Pipeline Drugs
  • API Manufacturers by US DMF Status (Drug Specific)
  • Drugs Market Data and Forecasted Sales Figure (2012-2016)
  • Marketed Drugs for End-Stage Kidney Disease
  • Drug Name
  • Drug Description
  • Global Active Pharmaceutical Manufacturers for Drug
  • Approval Status of Drug
  • Patent and Exclusivity Details for Drug
  • Company Profile and Financials
  • Phase III Drugs
  • United States Drug Master File (DMF)
  • Discontinued Drugs

For more information visit http://www.researchandmarkets.com/research/2s6vjm/endstage_kidney


<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 4210
Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.